EpiBiologics

EpiBiologics, based in San Mateo, CA, is at the forefront of developing directed protein degradation therapies designed to target and eliminate disease-causing proteins from the body. Their innovative EpiTAC platform utilizes a unique array of degradation-inducing protein receptors, enabling the creation of tissue-selective treatments for conditions such as cancer and autoimmune disorders.

The company's pioneering approach addresses a significant portion of the proteome that traditional intracellular degradation methods overlook, aiming to provide long-lasting therapeutic responses while minimizing impact on healthy tissues. With a skilled team dedicated to solving complex problems, EpiBiologics is committed to transforming patient care through new therapeutic options.

Generated from the website